Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

被引：0
|
作者：
Fischer, S. [1 ]
Klenske, E. [1 ]
Schmitt, H. [1 ]
Vitali, F. [1 ]
Hirschmann, S. [1 ]
Koch, F. [1 ]
Ramming, A. [2 ]
Zundler, S. [1 ]
Nagore, D. [3 ]
Uter, W. [4 ]
Neurath, M. F. [1 ]
Atreya, R. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 3, Erlangen, Germany
[3] Progent Biopharma, Derio, Spain
[4] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [31] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
  • [32] Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study
    Mazza, S.
    Fasci, A.
    Casini, V.
    Ricci, C.
    Munari, F.
    Pirola, L.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    O'Sed, N. Piazza
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Maurizio, V.
    Fiorino, G.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S342 - S342
  • [33] Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study
    Fischer, Sarah
    Donhauser, Moritz
    Cohnen, Sarah
    Fietkau, Konstantin
    Vetter, Marcel
    Gruebel-Liehr, Maria
    Dietrich, Peter
    Rath, Timo
    Wilfer, Angelika
    Sologub, Ludmilla
    Krebs, Sabine
    Doerje, Frank
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [34] Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study
    Fischer, Sarah
    Donhauser, Moritz
    Cohnen, Sarah
    Fietkau, Konstantin
    Vetter, Marcel
    Gruebel-Liehr, Maria
    Dietrich, Peter
    Rath, Timo
    Wilfer, Angelika
    Sologub, Ludmilla
    Krebs, Sabine
    Doerje, Frank
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [35] SAFETY AND CLINICAL EFFICACY OF DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTRE STUDY.
    Mazza, Stefano
    Fasci', Alberto
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Girelli, Carlo M.
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    O'Sed, Nicole Piazza
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    GASTROENTEROLOGY, 2020, 158 (06) : S957 - S957
  • [36] Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
    Mazza, Stefano
    Sed, Nicole Piazza O.
    Conforti, Francesco Simone
    Fasci, Alberto
    Rimondi, Alessandro
    Marinoni, Beatrice
    Casini, Valentina
    Ricci, Chiara
    Munari, Francesca
    Pirola, Lorena
    Invernizzi, Pietro
    Girelli, Carlo
    Lupinacci, Guido
    Pastorelli, Luca
    Cavallaro, Flaminia
    Ferraris, Luca
    Colucci, Alice
    Amato, Arnaldo
    Tontini, Gian Eugenio
    Vecchi, Maurizio
    Fiorino, Gionata
    Caprioli, Flavio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (01): : 172 - 181
  • [37] SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY
    Mazza, S.
    Sed, Piazza O. N.
    Conforti, F. S.
    Fasci, A.
    Casini, V
    Ricci, C.
    Munari, F.
    Pirola, L.
    Invernizzi, P.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Tontini, G. E.
    Vecchi, M.
    Fiorino, G.
    Caprioli, F.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S159 - S159
  • [38] Efficacy of Infliximab Biosimilar for Induction and Maintenance Therapy in Inflammatory Bowel Disease After Switch From Drug Originator: A Meta-Analysis
    Kashani, Amir
    Syal, Gaurav
    Bonthala, Nirupama
    McGovern, Dermot P. B.
    David, Shih
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S390 - S390
  • [39] The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
    Khan, Nabeel
    Patel, Dhruvan
    Pernes, Tyler
    Patel, Manthankumar
    Trivedi, Chinmay
    Medvedeva, Elina
    Xie, Dawei
    Yang, Yu-Xiao
    CROHNS & COLITIS 360, 2021, 3 (02)
  • [40] THREE MONTHS' CLINICAL OUTCOMES FROM A NATIONWIDE NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY ARTHRITIS. RESULTS FROM THE DANBIO REGISTRY
    Glintborg, B.
    Sorensen, I. Juul
    Jensen, D. Vendelbo
    Krogh, N. S.
    Loft, A. G.
    Colic, A.
    Espesen, J.
    Olsen, J.
    Hendricks, O.
    Grydehoj, J.
    Hansen, I. M. J.
    Sorensen, M. V.
    Chrysidis, S.
    Manilo, N.
    Klarlund, M.
    Andersen, L. S.
    Nordin, H.
    Kristensen, S.
    Hetland, M. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
12345